Loading patent…
AssigneeCelltrion Inc.
InventorsSoo Young Lee, Kye Sook Yi, Cheol Min Kim, Kyung Min Song, Yeon Jin Bae, Woo Joo Kim, Hee Jin Cheong, Joon Young Song, Man Seong Park, Ji Yun Noh
Estimating the term…
The present invention relates to a binding molecule having neutralizing activity against Middle East Respiratory Syndrome-Coronavirus (MERS-CoV). More particularly, the present invention relates to a binding molecule having strong ability to bind to an S protein of MERS-CoV and neutralizing activity against MERS-CoV and thus being very useful in the prevention, treatment or diagnosis of MERS-CoV infection.
A neutralizing binding molecule, which binds to a spike protein (S protein) on a surface of a Middle East Respiratory Syndrome-Coronavirus (MERS-CoV).
A nucleic acid molecule encoding a neutralizing binding molecule, which binds to a spike protein (S protein) on a surface of a Middle East Respiratory Syndrome-Coronavirus (MERS-CoV).
A composition for preventing or treating MERS-CoV infection comprising a neutralizing binding molecule, which binds to a spike protein (S protein) on a surface of a Middle East Respiratory Syndrome-Coronavirus (MERS-CoV).
A method of diagnosing, preventing or treating a disease caused by MERS-CoV infection comprising administering a neutralizing binding molecule, which binds to a spike protein (S protein) on a surface of a Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) in a therapeutically effective amount to a subject having a disease caused by MERS-CoV infection.
A kit for diagnosing MERS-CoV comprising a neutralizing binding molecule, which binds to a spike protein (S protein) on a surface of a Middle East Respiratory Syndrome-Coronavirus (MERS-CoV).
Dependencies are inferred from the claim text.